Invesco CEF Income Composite ETF (PCEF) Position Lowered by Raymond James Financial Services Advisors Inc.

Share on StockTwits

Raymond James Financial Services Advisors Inc. lowered its stake in Invesco CEF Income Composite ETF (NYSEARCA:PCEF) by 4.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 112,123 shares of the company’s stock after selling 5,645 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Invesco CEF Income Composite ETF were worth $2,268,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Advocacy Wealth Management Services LLC grew its position in Invesco CEF Income Composite ETF by 50.0% in the fourth quarter. Advocacy Wealth Management Services LLC now owns 1,500 shares of the company’s stock valued at $30,000 after acquiring an additional 500 shares during the last quarter. Capital Investment Advisory Services LLC bought a new position in Invesco CEF Income Composite ETF in the fourth quarter valued at about $96,000. Belpointe Asset Management LLC bought a new position in Invesco CEF Income Composite ETF in the third quarter valued at about $112,000. We Are One Seven LLC bought a new position in Invesco CEF Income Composite ETF in the fourth quarter valued at about $239,000. Finally, Baird Financial Group Inc. bought a new position in Invesco CEF Income Composite ETF in the third quarter valued at about $262,000.

Invesco CEF Income Composite ETF stock opened at $22.18 on Friday. Invesco CEF Income Composite ETF has a 12-month low of $19.33 and a 12-month high of $23.35.

The firm also recently announced a monthly dividend, which was paid on Thursday, February 28th. Shareholders of record on Wednesday, February 20th were given a $0.1518 dividend. This represents a $1.82 dividend on an annualized basis and a yield of 8.21%. The ex-dividend date was Tuesday, February 19th. This is a boost from Invesco CEF Income Composite ETF’s previous monthly dividend of $0.14.

COPYRIGHT VIOLATION WARNING: This news story was reported by Zolmax and is the property of of Zolmax. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://zolmax.com/investing/invesco-cef-income-composite-etf-pcef-position-lowered-by-raymond-james-financial-services-advisors-inc/2965193.html.

Invesco CEF Income Composite ETF Profile

PowerShares CEF Income Composite Portfolio (the Fund) seeks investment results that correspond generally to the price and yield performance of the S-Network Composite Closed-End Fund Index (the Index). The Fund will normally invest at least 80% of its total assets in securities of funds included in the Index.

Read More: Trading Ex-Dividend

Want to see what other hedge funds are holding PCEF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco CEF Income Composite ETF (NYSEARCA:PCEF).

Institutional Ownership by Quarter for Invesco CEF Income Composite ETF (NYSEARCA:PCEF)

Receive News & Ratings for Invesco CEF Income Composite ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco CEF Income Composite ETF and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

YEE  Reaches One Day Trading Volume of $180,142.00
YEE Reaches One Day Trading Volume of $180,142.00
Alibabacoin  Price Hits $0.0821 on Major Exchanges
Alibabacoin Price Hits $0.0821 on Major Exchanges
Sether  Trading 59.2% Higher  Over Last 7 Days
Sether Trading 59.2% Higher Over Last 7 Days
Dinero Price Tops $0.0022
Dinero Price Tops $0.0022
Critical Survey: Evofem Biosciences  versus Its Peers
Critical Survey: Evofem Biosciences versus Its Peers
Ocular Therapeutix  Stock Price Down 5.3%
Ocular Therapeutix Stock Price Down 5.3%


 
© 2006-2019 Zolmax.